GENEVA, Jan. 29, 2015 (GLOBE NEWSWIRE) -- ESPERITE, the European leader since 2000 in the stem cells life science business, is launching unique new-generation genetic tests. Risk-free, convenient, affordable and accurate tests with results available in a few days. ESPERITE eases its clients the key genetic information to personalize their health-related decisions, fostering a new culture of consumer empowerment towards a proactive approach to health.
ESPERITE, through its predictive medicine arm GENOMA SA, is at the forefront of technological and scientific innovation. ESPERITE is announcing a multimillion investment to assemble the largest genetic platform for clinical diagnostics in Europe. A highly efficient NGS platform with the capacity to process 75'000 samples per year as of today. ESPERITE signed a supply agreement with Thermo Fisher Life Technology to install satellite sequencing platforms in the countries where ESPERITE operates, all connected to its NGS Cloud.
Frederic Amar, CEO of ESPERITE group: "Our dream is a reality today. We are improving the way we understand and address human disease by leading transformative research and translating it into tangible benefits for society. 2015 marks the beginning of a new era for personalized medicine". ESPERITE is leading this paradigm shift and will communicate shortly new developments.
ESPERITE group, listed at Euronex Amsterdam and Paris, is the leading international company in regenerative and predictive medicine, operational in 40 countries with a network of 6'000 clinics worldwide. ESPERITE serves clients in its state-of-the-art lab facilities in Geneva coupled with ultra-modern processing and storage facilities in Belgium, Switzerland, Germany, Dubai, South Africa and Portugal Its family stem cell bank, CryoSave, stores almost 275'000 samples from umbilical cord blood and cord tissue.